Therapy (HCV)
Non-Responders To Interferon Profit From Adding Ribavirin To Regimen
Published in Hepatitis Weekly, March 19th, 2001
Physicians commonly give interferon (IFN) to HCV patients as a first choice of treatment. However, some patients fail to benefit from IFN. Their viral levels remain high even after extended periods of taking treatments.
A controlled study performed at Saint Louis University School of Medicine indicates a second round of interferon therapy that adds ribavirin to the regimen could benefit a majority of initial non-responders.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2001-03-19)
More Articles from Hepatitis Weekly
- Autoimmune Hepatitis
Cholangiography Best For Differentiating Sclerosing Cholangitis From AIH - Pathogenesis
Hepatitis C Virus Clamps Onto Protein Synthesis Machinery - Therapy (HCV)
Time Factor And RNA Levels Predict Sustained Response - At-Risk Populations
Injection Drug Users At Needle Exchange Program Share Few Syringes, And Those Who Do Share With Friends - Hepatic Steatosis
Obesity And Liver Fibrosis Common To Chinese HCV Patients With Fatty Liver - Hepatocellular Carcinoma
Careful Evaluation Should Precede Adoption Of Surveillance Programs - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
